AU2003274822B2 - Intracellular delivery of biological effectors - Google Patents

Intracellular delivery of biological effectors Download PDF

Info

Publication number
AU2003274822B2
AU2003274822B2 AU2003274822A AU2003274822A AU2003274822B2 AU 2003274822 B2 AU2003274822 B2 AU 2003274822B2 AU 2003274822 A AU2003274822 A AU 2003274822A AU 2003274822 A AU2003274822 A AU 2003274822A AU 2003274822 B2 AU2003274822 B2 AU 2003274822B2
Authority
AU
Australia
Prior art keywords
peptide
transporter
effector
multimeric
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2003274822A
Other languages
English (en)
Other versions
AU2003274822A1 (en
Inventor
Christophe Bonny
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Xigen SA
Original Assignee
Xigen SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xigen SA filed Critical Xigen SA
Publication of AU2003274822A1 publication Critical patent/AU2003274822A1/en
Assigned to XIGEN SA reassignment XIGEN SA Request for Assignment Assignors: Universtiry of Lausanne
Application granted granted Critical
Publication of AU2003274822B2 publication Critical patent/AU2003274822B2/en
Priority to AU2008201592A priority Critical patent/AU2008201592C1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/04—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
    • C07K1/047—Simultaneous synthesis of different peptide species; Peptide libraries
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1013—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1019—Tetrapeptides with the first amino acid being basic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1021—Tetrapeptides with the first amino acid being acidic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/81—Carrier - bound or immobilized peptides or proteins and the preparation thereof, e.g. biological cell or cell fragment as carrier

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Analytical Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Virology (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
AU2003274822A 2002-06-07 2003-06-06 Intracellular delivery of biological effectors Ceased AU2003274822B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2008201592A AU2008201592C1 (en) 2002-06-07 2008-04-10 Intracellular Delivery of Biological Effectors

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/165,015 US7033597B2 (en) 2000-10-13 2002-06-07 Intracellular delivery of biological effectors
US10/165,015 2002-06-07
PCT/IB2003/003097 WO2003103718A2 (en) 2002-06-07 2003-06-06 Intracellular delivery of biological effectors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2008201592A Division AU2008201592C1 (en) 2002-06-07 2008-04-10 Intracellular Delivery of Biological Effectors

Publications (2)

Publication Number Publication Date
AU2003274822A1 AU2003274822A1 (en) 2003-12-22
AU2003274822B2 true AU2003274822B2 (en) 2008-01-17

Family

ID=29732051

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003274822A Ceased AU2003274822B2 (en) 2002-06-07 2003-06-06 Intracellular delivery of biological effectors

Country Status (6)

Country Link
US (2) US7033597B2 (enExample)
EP (1) EP1511763A2 (enExample)
JP (2) JP4514607B2 (enExample)
AU (1) AU2003274822B2 (enExample)
CA (1) CA2488716A1 (enExample)
WO (1) WO2003103718A2 (enExample)

Families Citing this family (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8183339B1 (en) 1999-10-12 2012-05-22 Xigen S.A. Cell-permeable peptide inhibitors of the JNK signal transduction pathway
US20040082509A1 (en) 1999-10-12 2004-04-29 Christophe Bonny Cell-permeable peptide inhibitors of the JNK signal transduction pathway
JP2003535208A (ja) 2000-06-08 2003-11-25 ラ ホヤ ファーマシューティカル カンパニー 高分子量ポリエチレン・オキシドを含む多価プラットホーム分子
WO2004067778A2 (en) * 2003-01-28 2004-08-12 University Of South Florida Differentially expressed genes in large granular lymphocyte leukemia
CA2516685A1 (en) 2003-02-20 2004-09-02 University Of South Florida Peptidomimetic inhibitors of stat3 activity and their medical uses
WO2004094463A2 (en) * 2003-04-18 2004-11-04 University Of Florida Research Foundation, Inc. Peptide inhibitors of autophosphorylation protein kinases
WO2005016946A2 (en) * 2003-08-13 2005-02-24 University Of South Florida Platinum complexes for the treatment of tumors
US8227434B1 (en) 2003-11-04 2012-07-24 H. Lee Moffitt Cancer Center & Research Institute, Inc. Materials and methods for treating oncological disorders
US20050288365A1 (en) * 2004-01-06 2005-12-29 Heidi Kay Platinum complexes and methods for inhibiting tumor cell proliferation
US8669376B2 (en) 2004-02-17 2014-03-11 University Of South Florida Cytotoxin compounds and methods of isolation
WO2005079471A2 (en) 2004-02-17 2005-09-01 University Of South Florida Cytotoxin compound and method of isolation
US8080517B2 (en) 2005-09-12 2011-12-20 Xigen Sa Cell-permeable peptide inhibitors of the JNK signal transduction pathway
WO2007031098A1 (en) 2005-09-12 2007-03-22 Xigen S.A. Cell-permeable peptide inhibitors of the jnk signal transduction pathway
US20100247427A1 (en) * 2005-10-14 2010-09-30 University Of South Florida Methods of inhibiting cell growth and methods of enhancing radiation responses
DE102006040647A1 (de) * 2006-08-30 2008-03-13 Robert Bosch Gmbh Handwerkzeugmaschine
WO2008079945A2 (en) * 2006-12-20 2008-07-03 University Of South Florida Rock inhibitors and uses thereof
ES2668537T3 (es) * 2007-07-13 2018-05-18 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Péptidos antimicrobianos derivados de virus
WO2009143865A1 (en) 2008-05-30 2009-12-03 Xigen S.A. Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
WO2009143864A1 (en) 2008-05-30 2009-12-03 Xigen S.A. Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of chronic or non-chronic inflammatory digestive diseases
US8673910B2 (en) * 2008-06-30 2014-03-18 H. Lee Moffitt Cancer Center And Research Institute Proteasome inhibitors for selectively inducing apoptosis in cancer cells
WO2010011666A2 (en) * 2008-07-21 2010-01-28 University Of South Florida Indoline scaffold shp-2 inhibitors and cancer treatment method
CN102215860A (zh) * 2008-08-05 2011-10-12 南佛罗里达大学 治疗认知损害的方法
US9132168B2 (en) 2008-08-05 2015-09-15 University Of South Florida Methods of treating cognitive impairment
WO2010072228A1 (en) * 2008-12-22 2010-07-01 Xigen S.A. Novel transporter constructs and transporter cargo conjugate molecules
US8715685B2 (en) * 2009-07-14 2014-05-06 Lucia Irene Gonzalez Stereoisomer peptides and their polymer conjugates for HIV disease
US9221808B2 (en) 2010-04-16 2015-12-29 H. Lee Moffitt Cancer Center And Research Institute, Inc. Pyridylthiazole-based ureas as inhibitors of Rho associated protein kinase (ROCK) and methods of use
WO2011160653A1 (en) 2010-06-21 2011-12-29 Xigen S.A. Novel jnk inhibitor molecules
AU2010362444B2 (en) 2010-10-14 2015-08-06 Xigen Inflammation Ltd. Use of cell-permeable peptide inhibitors of the JNK signal transduction pathway for the treatment of chronic or non-chronic inflammatory eye diseases
US9616064B2 (en) 2011-03-30 2017-04-11 H. Lee Moffitt Cancer Center And Research Institute, Inc. Rho kinase inhibitors and methods of use
WO2013091670A1 (en) 2011-12-21 2013-06-27 Xigen S.A. Novel jnk inhibitor molecules for treatment of various diseases
US9409868B2 (en) 2012-01-24 2016-08-09 H. Lee Moffin Cancer Center and Research Institute, Inc. Inhibitors of rho associated protein kinases (ROCK) and methods of use
JP6233812B2 (ja) 2012-03-07 2017-11-22 エイチ リー モフィット キャンサー センター アンド リサーチ インスティテュート インコーポレイテッド 選択的ヒストンデアセチラーゼ６阻害剤
US10098967B2 (en) 2012-12-03 2018-10-16 Ohio State Innovation Foundation Self-assembly of therapeutic agent-peptide nanostructures
US10253099B2 (en) 2012-12-05 2019-04-09 Ruprecht-Karls-Universität Heidelberg Conjugates of proteins and multivalent cell-penetrating peptides and their uses
DK2970463T3 (en) * 2013-03-13 2018-01-22 Biocrine Ab METHOD OF TREATING AND / OR LIMITING THE DEVELOPMENT OF DIABETES
AU2014301631A1 (en) 2013-06-26 2015-08-27 Xigen Inflammation Ltd. New use of cell-permeable peptide inhibitors of the JNK signal transduction pathway for the treatment of various diseases
WO2015197097A1 (en) 2014-06-26 2015-12-30 Xigen Inflammation Ltd. New use for jnk inhibitor molecules for treatment of various diseases
WO2014206427A1 (en) 2013-06-26 2014-12-31 Xigen Inflammation Ltd. New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
US9850216B2 (en) 2013-08-06 2017-12-26 H. Lee Moffitt Cancer Center And Research Institute, Inc. Inhibitors of ACK1/TNK2 tyrosine kinase
US9950036B2 (en) 2013-08-21 2018-04-24 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Treatment of mood and stress related disorders
US10626178B2 (en) 2013-08-21 2020-04-21 Raz Yirmiya Treatment of mood and stress related disorders
EP3097088A4 (en) 2014-01-23 2017-10-04 H. Lee Moffitt Cancer Center And Research Institute, Inc. Icariin derivatives
WO2015112904A1 (en) 2014-01-24 2015-07-30 University Of Florida Research Foundation, Inc. Socs mimetics for the treatment of diseases
WO2015116782A1 (en) 2014-01-29 2015-08-06 Board Of Regents, The University Of Texas System Nucleobase analogue derivatives and their applications
US10197575B2 (en) 2014-03-31 2019-02-05 H. Lee Moffitt Cancer Center And Research Institute, Inc. Stabilized peptoid-peptide hybrids and uses thereof
WO2015157162A1 (en) 2014-04-06 2015-10-15 H. Lee Moffitt Cancer Center And Research Institute, Inc. Histone deacetylase as a modulator of pdl1 expression and activity
EP3154350B1 (en) 2014-04-10 2024-03-27 H. Lee Moffitt Cancer Center And Research Institute, Inc. Enhanced expansion of tumor-infiltrating lymphocytes for adoptive cell therapy
SI3149025T1 (sl) 2014-05-21 2019-09-30 Entrada Therapeutics, Inc. V celico prodirajoči peptidi in postopki njihove izdelave in uporabe
US10815276B2 (en) 2014-05-21 2020-10-27 Entrada Therapeutics, Inc. Cell penetrating peptides and methods of making and using thereof
US10456443B2 (en) 2014-08-27 2019-10-29 Ohio State Innovation Foundation Peptidyl calcineurin inhibitors
US10118942B2 (en) 2015-03-26 2018-11-06 H. Lee Moffitt Cancer Center And Research Institute, Inc. Toll-like receptor 2 ligands and methods of making and using thereof
AU2016258123A1 (en) 2015-05-06 2018-01-04 H. Lee Moffitt Cancer Center And Research Institute, Inc. Radiotherapeutic and companion imaging agents to target MC1R
CN106714836A (zh) 2015-06-05 2017-05-24 H·李·莫菲特癌症中心研究有限公司 Gm‑csf/cd40l疫苗和检查点抑制剂联合治疗
AU2016301212A1 (en) 2015-08-02 2018-03-29 H. Lee Moffitt Cancer Center And Research Institute, Inc. Inhibitors of ACK1/TNK2 tyrosine kinase
WO2017049307A1 (en) 2015-09-17 2017-03-23 Ohio State Innovation Foundation Carborane compounds and methods of use thereof
US10738016B2 (en) 2015-10-13 2020-08-11 H. Lee Moffitt Cancer Center And Research Institute, Inc. BRD4-kinase inhibitors as cancer therapeutics
JP2018536426A (ja) 2015-12-09 2018-12-13 ヴァンダービルト ユニヴァーシティ ミクロモノスポラ・カルボナセア変種アウランティアカ（Ｍｉｃｒｏｍｏｎｏｓｐｏｒａ ｃａｒｂｏｎａｃｅａ ｖａｒ ａｕｒａｎｔｉａｃａ）におけるエベルニノマイシンアナログの生合成
US11203576B2 (en) 2016-03-11 2021-12-21 H. Lee Moffitt Cancer Center And Research Institute, Inc. Aurora kinase and Janus kinase inhibitors for prevention of graft versus host disease
JP7264642B2 (ja) 2016-03-16 2023-04-25 エイチ リー モフィット キャンサー センター アンド リサーチ インスティテュート インコーポレイテッド エフェクターｔ細胞機能を増進するための、セレブロンを標的とする小分子
EP3452110A4 (en) 2016-05-04 2019-12-25 H. Lee Moffitt Cancer Center And Research Institute, Inc. AGENT FOR THE MOLECULAR IMAGING AND IMMUNOTHERAPY OF CANCER DISEASES TARGETING THE DELTA OPIOID RECEPTOR
CN110114075B (zh) 2016-11-09 2024-01-12 俄亥俄州国家创新基金会 含有二硫化物的细胞穿透肽及其制备和使用方法
TW202500573A (zh) 2016-11-22 2025-01-01 俄亥俄州立創新基金會 細胞穿透肽序列
US11352394B2 (en) 2016-11-22 2022-06-07 Ohio State Innovation Foundation Cyclic cell penetrating peptides comprising beta-hairpin motifs and methods of making and using thereof
US10913773B2 (en) 2016-11-22 2021-02-09 Ohio State Innovation Foundation Bicyclic peptidyl inhibitor of tumor necrosis factor-alpha
US11583525B2 (en) 2017-06-06 2023-02-21 H. Lee Moffitt Cancer Center And Research Institute, Inc. Geranylgeranyltransferase I inhibitor for treatment of a PTEN defective cancer
WO2019070962A1 (en) 2017-10-04 2019-04-11 Ohio State Innovation Foundation BICYCLIC PEPTIDE INHIBITORS
CN117567639A (zh) 2017-10-27 2024-02-20 俄亥俄州国家创新基金会 用于细胞内递送装订肽的多肽缀合物
US11793884B2 (en) 2018-01-29 2023-10-24 Ohio State Innovation Foundation Cyclic peptidyl inhibitors of CAL-PDZ binding domain
US11576946B2 (en) 2018-01-29 2023-02-14 Ohio State Innovation Foundation Peptidyl inhibitors of calcineurin-NFAT interaction
CA3092062A1 (en) 2018-02-22 2019-08-29 Entrada Therapeutics, Inc. Compositions and methods for treating mitochondrial neurogastrointestinal encephalopathy
EP3787671A4 (en) 2018-05-04 2022-06-15 Ohio State Innovation Foundation NON-PEPTIDE CELL-PENETRATING MOTIFS
US11987647B2 (en) 2018-05-09 2024-05-21 Ohio State Innovation Foundation Cyclic cell-penetrating peptides with one or more hydrophobic residues
JP2021532077A (ja) 2018-07-11 2021-11-25 エイチ リー モフィット キャンサー センター アンド リサーチ インスティテュート インコーポレイテッド セレブロン系機構に対抗する二量体免疫調節化合物
US10898460B1 (en) 2018-07-20 2021-01-26 University Of South Florida Leishmania inhibitors
US11987568B2 (en) 2018-08-03 2024-05-21 H. Lee Moffitt Cancer Center And Research Institute, Inc. Allosteric inhibitor of WEE1 kinase
US12319685B2 (en) 2018-08-17 2025-06-03 H. Lee Moffitt Cancer Center And Research Institute, Inc. Small molecule pyrin-domain targeted NLRP3 inflammasome inhibitors
WO2020081918A2 (en) 2018-10-18 2020-04-23 H. Lee Moffitt Cancer Center And Research Institute, Inc. Βeta-catenin and b-cell lymphoma 9 (bcl9) inhibitors
US12269899B2 (en) 2018-12-07 2025-04-08 H. Lee Moffitt Cancer Center And Research Institute, Inc. Peptidomimetic inhibitors of β-catenin/Tcf protein-protein interaction
JP2023501385A (ja) 2019-11-08 2023-01-18 ユニバーシティ オブ ピッツバーグ － オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション 抗微生物ペプチドを含む組成物
KR102811112B1 (ko) 2020-01-20 2025-05-21 삼성전자주식회사 매립형 공기청정장치
WO2021150954A1 (en) 2020-01-24 2021-07-29 Ohio State Innovation Foundation Bacterial topoisomerase inhibitors derived from isomannide
WO2021236852A1 (en) 2020-05-20 2021-11-25 Sana Biotechnology, Inc. Methods and compositions for treatment of viral infections
CA3212944A1 (en) 2021-03-31 2022-10-06 Patrick Dougherty Cyclic cell penetrating peptides
US12371463B2 (en) 2021-04-20 2025-07-29 University of Pittsburgh—of the Commonwealth System of Higher Education Methods and compositions for treatment of antibiotic-resistant bacterial infections
JP2024518068A (ja) 2021-05-10 2024-04-24 エントラーダ セラピューティクス，インコーポレイティド 細胞内治療のための組成物及び方法
JP2024518476A (ja) 2021-05-10 2024-05-01 エントラーダ セラピューティクス，インコーポレイティド ｍＲＮＡスプライシングを調節するための組成物及び方法
WO2022240721A1 (en) 2021-05-10 2022-11-17 Entrada Therapeutics, Inc. Compositions and methods for modulating interferon regulatory factor-5 (irf-5) activity
KR20240038967A (ko) 2021-06-23 2024-03-26 엔트라다 테라퓨틱스, 인크. Cug 반복을 표적화하기 위한 안티센스 화합물 및 방법
JP2024532464A (ja) 2021-09-01 2024-09-05 エントラーダ セラピューティクス，インコーポレイティド デュシェンヌ型筋ジストロフィーにおいてエクソン４４をスキッピングするための化合物及び方法
WO2023219933A1 (en) 2022-05-09 2023-11-16 Entrada Therapeutics, Inc. Compositions and methods for delivery of nucleic acid therapeutics
KR20250039397A (ko) 2022-07-15 2025-03-20 엔트라다 테라퓨틱스, 인크. 하이브리드 올리고뉴클레오티드
WO2024073042A1 (en) 2022-09-30 2024-04-04 Entrada Therapeutics, Inc. Ocular delivery of therapeutic agents
EP4626905A1 (en) * 2022-12-01 2025-10-08 Hairvel Oü Novel peptide conjugates
WO2025038901A1 (en) 2023-08-17 2025-02-20 Entrada Therapeutics, Inc. Cyclic peptides for delivering therapeutics
WO2025038902A2 (en) 2023-08-17 2025-02-20 Entrada Therapeutics, Inc. Intracellular targeting of oligonucleotides
WO2025072246A1 (en) 2023-09-26 2025-04-03 Entrada Therapeutics, Inc. Compounds and methods for skipping exon 50 in duchenne muscular dystrophy

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994023751A1 (de) * 1993-04-14 1994-10-27 Boehringer Mannheim Gmbh Nukleinsäure-transferpeptide und deren verwendung zur einschleusung von nukleinsäuren in eukaryontische zellen
FR2767323A1 (fr) * 1997-08-12 1999-02-19 Synt Em Peptides lineaires derives de peptides antibiotiques, leur preparation et leur utilisation pour vectoriser des substances actives
WO2000012587A2 (en) * 1998-08-28 2000-03-09 Gryphon Sciences Polyamide chains of precise length, methods to manufacture them and their conjugates
WO2002031109A2 (en) * 2000-10-13 2002-04-18 University Of Lausanne Intracellular delivery of biological effectors by novel transporter peptide sequences

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07505283A (ja) * 1992-03-20 1995-06-15 ベイラー・カレッジ・オブ・メディシン Ｄｎａトランスポーター系および使用方法
WO1993019768A1 (en) * 1992-04-03 1993-10-14 The Regents Of The University Of California Self-assembling polynucleotide delivery system
CA2094658A1 (en) 1992-04-23 1993-10-24 Martin Sumner-Smith Intracellular delivery of biochemical agents
US6361938B1 (en) 1996-11-08 2002-03-26 Elan Corporation, Plc Peptides which enhance transport across tissues and methods of identifying and using the same
CA2290756A1 (en) 1997-05-15 1998-11-19 Cytogen Corporation Random peptides that bind to gastro-intestinal tract (git) transport receptors and related methods
KR20010012809A (ko) * 1997-05-21 2001-02-26 더 보드 오브 트러스티스 오브 더 리랜드 스탠포드 쥬니어 유니버시티 생체막을 통한 수송을 증진시키는 조성물 및 방법
FR2766826B1 (fr) 1997-08-04 2001-05-18 Pasteur Institut Vecteurs derives d'anticorps pour le transfert de substances dans les cellules
DK1102785T3 (da) * 1999-06-07 2013-05-13 Arrowhead Res Corp Sammensætninger til lægemiddeltilførsel ved anvendelse af pH-følsomme molekyler
US20030104622A1 (en) * 1999-09-01 2003-06-05 Robbins Paul D. Identification of peptides that facilitate uptake and cytoplasmic and/or nuclear transport of proteins, DNA and viruses
FR2805821B1 (fr) 2000-03-01 2004-01-16 Diatos Sequences d'acides amines facilitant la penetration d'une substance d'interet a l'interieur des cellules et/ou des noyaux cellulaires

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994023751A1 (de) * 1993-04-14 1994-10-27 Boehringer Mannheim Gmbh Nukleinsäure-transferpeptide und deren verwendung zur einschleusung von nukleinsäuren in eukaryontische zellen
FR2767323A1 (fr) * 1997-08-12 1999-02-19 Synt Em Peptides lineaires derives de peptides antibiotiques, leur preparation et leur utilisation pour vectoriser des substances actives
WO2000012587A2 (en) * 1998-08-28 2000-03-09 Gryphon Sciences Polyamide chains of precise length, methods to manufacture them and their conjugates
WO2002031109A2 (en) * 2000-10-13 2002-04-18 University Of Lausanne Intracellular delivery of biological effectors by novel transporter peptide sequences

Also Published As

Publication number Publication date
AU2003274822A1 (en) 2003-12-22
JP4514607B2 (ja) 2010-07-28
US7033597B2 (en) 2006-04-25
US20060178310A1 (en) 2006-08-10
WO2003103718A2 (en) 2003-12-18
CA2488716A1 (en) 2003-12-18
WO2003103718A3 (en) 2004-11-25
EP1511763A2 (en) 2005-03-09
US20030032594A1 (en) 2003-02-13
JP2006500917A (ja) 2006-01-12
JP2010024250A (ja) 2010-02-04

Similar Documents

Publication Publication Date Title
AU2003274822B2 (en) Intracellular delivery of biological effectors
US7034109B2 (en) Intracellular delivery of biological effectors
AU723694B2 (en) Exendin analogues, processes for their preparation and medicaments containing them
Freeman et al. Microwave-assisted solid-phase aza-peptide synthesis: aza scan of a PKB/Akt inhibitor using aza-arginine and aza-proline precursors
Friedler et al. Backbone cyclic peptide, which mimics the nuclear localization signal of human immunodeficiency virus type 1 matrix protein, inhibits nuclear import and virus production in nondividing cells
US20150038671A1 (en) Efficient Synthesis of CN2097 and RC7 and Their Analogs
Ciulla et al. Nature-inspired and medicinally relevant short peptides
Parthasarathy et al. The medicinal chemistry of therapeutic peptides: Recent developments in synthesis and design optimizations
Mezö et al. Synthesis of Gonadotropin-Releasing Hormone III Analogs. Structure− Antitumor Activity Relationships
Appiah Kubi et al. Designing cell-permeable macrocyclic peptides
Konieczny et al. N-terminus to arginine side-chain cyclization of linear peptidic neuropeptide Y Y4 receptor ligands results in picomolar binding constants
JP3805679B2 (ja) 新規のｌｈｒｈ拮抗物質、その製造および医薬としてのその使用
Cruz et al. Total solid-phase synthesis of marine cyclodepsipeptide IB-01212
AU2008201592B2 (en) Intracellular Delivery of Biological Effectors
Kubi et al. Cell-penetrating and mitochondrion-targeting molecules
Shi et al. α/Sulfono-γ-AA peptide hybrids agonist of GLP-1R with prolonged action both in vitro and in vivo
CA2606894A1 (en) Novel compounds as glp-i agonists
JP4927746B2 (ja) 樹脂上ペプチド環化
AU2007216926A1 (en) Intracellular Delivery of Biological Effectors by Novel Transporter Peptide Sequences
CN101223189A (zh) 作为glp-i激动剂的新颖化合物
Chen et al. Chemobodies as Targeting Moieties of Insulin-Secreting Cells
Jessop Molecular transporters for drug delivery: Guanidinium-based and nanotube transporters
Zamudio Vázquez Synthesis, Biological Evaluation and Insights into the Mode of Action of Quinoxaline Containing Peptides

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: XIGEN SA

Free format text: FORMER APPLICANT(S): UNIVERSTIRY OF LAUSANNE

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired